Planning Capital Management Corp Summit Therapeutics Inc. Transaction History
Planning Capital Management Corp
- $151 Billion
- Q3 2024
A detailed history of Planning Capital Management Corp transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Planning Capital Management Corp holds 1 shares of SMMT stock, worth $21. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$21% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
150Shares Held
66.3MCall Options Held
1.05MPut Options Held
1.07M-
Baker Bros. Advisors LP New York, NY23.2MShares$490 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$186 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$87 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$62.5 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.25B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...